Using electroacupuncture and acupressure to prevent hand-foot syndrome in breast cancer patients on capecitabine

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of combining electroacupuncture with self-administered acupressure to prevent Hand-Foot Syndrome (HFS) in patients with malignant tumors undergoing treatment with capecitabine. It is a randomized controlled trial where participants are assigned to either a true treatment group or a sham treatment group, both receiving doctor-prescribed care. The study aims to assess the severity and duration of HFS symptoms while enhancing the quality of life for patients during their cancer treatment. The HFS-14 questionnaire will be utilized to evaluate patient conditions throughout the treatment cycles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Sign a written informed consent form;
2. Male or female ≥ 18 years old;
3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label;
4. The performance status of the Eastern Cancer Collaboration Group is 0-2;
5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg/m\^2);
6. Expected lifespan ≥ 3 months;
7. Laboratory requirements: platelet count ≥ 100 × 10\^9/L, white blood cell count\>3.0 × 10\^9/L, hemoglobin ≥ 10.0 g/dL, normal liver and kidney function;
8. Adequate contraception.

Exclusion Criteria:

1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy;
2. The initial dose of capecitabine is less than 800mg/m\^2;
3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment;
4. Skin diseases that may interfere with clinical trial results;
5. Known drug/alcohol abuse;
6. Pregnant women or lactating patients;
7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive);
8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine;
9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture;
10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy.
11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.

Where it's running

• Qinghai University Affiliated Hospital
  Xining, Qinghai, China Recruiting

Study contacts

• Study coordinator: Jiuda Zhao
• Email: jiudazhao@126.com
• Phone: 869716230893

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• Evaluating new imaging technology for cancer radiation therapy

  This study is testing a new imaging technology for cancer radiation therapy to see if it can provide better pictures than the standard method, helping patients get more effective treatment.

  Recruiting at 4 sites Varian, a Siemens Healthineers Company · Columbus, Ohio and 3 other locations · NCT06681233

• Electroacupuncture plus self-acupressure to improve quality of life during chemotherapy for early-stage breast cancer

  This trial tests whether adding electroacupuncture together with self-acupressure can improve quality of life for people with early-stage breast cancer who are receiving chemotherapy.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT06601621

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.